Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by CenterBook Partners LP

CenterBook Partners LP lessened its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 17.1% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 12,837 shares of the biopharmaceutical company’s stock after selling 2,649 shares during the period. CenterBook Partners LP’s holdings in Regeneron Pharmaceuticals were worth $9,734,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently modified their holdings of REGN. Western Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the 1st quarter valued at about $26,000. Armstrong Advisory Group Inc. grew its holdings in Regeneron Pharmaceuticals by 466.7% in the third quarter. Armstrong Advisory Group Inc. now owns 34 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 28 shares during the period. Mowery & Schoenfeld Wealth Management LLC bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $29,000. Trust Co. of Vermont bought a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $29,000. Finally, Fiduciary Financial Advisors purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter valued at approximately $29,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 0.2%

Shares of NASDAQ:REGN traded up $1.45 during trading on Friday, reaching $904.35. 1,122,229 shares of the stock traded hands, compared to its average volume of 793,479. The stock has a 50-day moving average of $804.38 and a two-hundred day moving average of $742.81. Regeneron Pharmaceuticals, Inc. has a 52-week low of $591.52 and a 52-week high of $991.73. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.66 and a current ratio of 3.35. The stock has a market cap of $93.11 billion, a P/E ratio of 19.97, a price-to-earnings-growth ratio of 1.51 and a beta of 0.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Friday, October 30th. The biopharmaceutical company reported $20.07 earnings per share for the quarter, beating the consensus estimate of $16.51 by $3.56. The company had revenue of $5.12 billion during the quarter, compared to the consensus estimate of $4.58 billion. Regeneron Pharmaceuticals had a net margin of 28.51% and a return on equity of 16.01%. The firm’s quarterly revenue was up 36.3% compared to the same quarter last year. During the same quarter last year, the firm earned $11.83 earnings per share. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 58.26 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, December 3rd. Shareholders of record on Friday, November 20th will be issued a $0.94 dividend. The ex-dividend date of this dividend is Friday, November 20th. This represents a $3.76 dividend on an annualized basis and a dividend yield of 0.4%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 8.30%.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. Weiss Ratings raised Regeneron Pharmaceuticals from a “hold (c)” rating to a “hold (c+)” rating in a research report on Monday. BMO Capital Markets lifted their price objective on Regeneron Pharmaceuticals from $800.00 to $920.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. Wells Fargo & Company boosted their target price on Regeneron Pharmaceuticals from $750.00 to $925.00 and gave the stock an “equal weight” rating in a report on Monday, November 2nd. Royal Bank Of Canada increased their target price on Regeneron Pharmaceuticals from $810.00 to $913.00 and gave the stock a “sector perform” rating in a research note on Monday, November 2nd. Finally, Canaccord Genuity Group raised their price target on Regeneron Pharmaceuticals from $875.00 to $922.00 and gave the company a “buy” rating in a report on Wednesday, October 28th. One research analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $898.97.

Insider Transactions at Regeneron Pharmaceuticals

In related news, insider Andrew J. Murphy sold 4,147 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $772.70, for a total transaction of $3,204,386.90. Following the sale, the insider directly owned 47,833 shares of the company’s stock, valued at $36,960,559.10. This trade represents a 7.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Christine A. Poon sold 7,830 shares of Regeneron Pharmaceuticals stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $969.09, for a total value of $7,587,974.70. Following the completion of the sale, the director owned 5,219 shares of the company’s stock, valued at $5,057,680.71. The trade was a 60.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 28,228 shares of company stock valued at $25,985,950. Insiders own 6.97% of the company’s stock.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious diseases. Its research and product portfolio spans areas including eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disorders, infectious diseases and rare conditions.

The company’s medicines include EYLEA for certain eye diseases, Dupixent for inflammatory conditions and Libtayo for cancer. Regeneron also develops and markets treatments with pharmaceutical partners, including Sanofi, and its products reach patients in the United States and international markets through its own operations and collaborations.

Founded in 1988, Regeneron is headquartered in Tarrytown, New York.